|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Asthma, Copd and Allergic Rhinitis - The Needs of Severe Patients Must be Addressed
Datamonitor, May 2003, Pages: 292
Both allergic rhinitis and asthma are well served by current therapies.
Greater uptake of combination therapies for asthma and Copd, and rising genericization in all sectors provide additional barriers to market entry for novel therapeutics.
Copd is massively under-diagnosed, but the lack of effective therapies will continue to hamper attempts to increase patient awareness.
Scope:
- Evaluation of the prevalence of asthma, Copd and allergic rhinitis in the seven leading country markets
- Identification of clinical and environmental unmet needs in each of the three major respiratory markets
- Profiles of the leading global players: GlaxoSmithKline, Merck, Aventis, Pfizer, Schering-Plough, AstraZeneca, Novartis
- In depth profiles of key drugs in late-stage development, including an evaluation of clinical trial data and an assessment of unmet need satisfaction
Report Highlights:
Despite the fact that over 90% of asthmatics are well-managed on current therapies, the majority of R&D products are targeted at the asthma market. The greatest potential for products like Xolair is in allergic rhinitis, as 75% of asthmatics suffer from concomitant allergic rhinitis, and aggressive treatment may lead to improved asthma management.
The key unmet need in the Copd sector is effective therapies, yet pipelines are littered with clinical failures, highlighting the difficulty in reversing the effects of destroyed lung tissue. Irrespective of their modest efficacy, Pde-4 inhibitors will be welcomed by the Copd community.
Reasons to Purchase:
- Plan new product development to meet identified unmet needs in the Copd sector
- Evaluate the market potential of late-stage developmental products, and of innovative, early-stage drugs
- Recognize competitive market dynamics within the respiratory sector with an assessment of company portfolios and strategies
Customers who bought this item also bought
Pipeline Insight: Asthma, COPD and Allergic Rhinitis - Weak Late Stage Pipeline Leaves Innovation to Phase I/II Candidates
The Asthma, COPD & Allergic Rhinitis Market Outlook to 2011
Pipeline Insight: Asthma/COPD/Allergic Rhinitis - As Patents Expire, Novel Combinations Inspire
Commercial and Pipeline Insight: Allergic Rhinitis
Pipeline Insight: Asthma/COPD - Targeted Therapies on the Horizon
Asthma & COPD Therapeutics
Commercial Insight: Asthma and Copd - Combinations breathe life into the asthma and Copd markets
Commercial Insight: Asthma & COPD - On the verge of generic entry
Commercial Insight: Asthma & COPD - Combination products still have blockbuster potential
Asthma And COPD - Get Smart
Strategic Perspectives: Allergic Rhinitis - Impact of a blockbuster going bust
Asthma and COPD Drug Discoveries: What the Future Holds
|
|
|
|
